This model was broadly used for radiolabeled gastrin analogue development and the preclinical evaluation of pharmacokinetics, biodistribution, dosimetry or toxicity, required for regulatory approval of a phase I clinical trial with MTC patients 20. The gene discussed is GAST; the disease is medullary thyroid gland carcinoma.